JPS6232169B2 - - Google Patents
Info
- Publication number
- JPS6232169B2 JPS6232169B2 JP12250079A JP12250079A JPS6232169B2 JP S6232169 B2 JPS6232169 B2 JP S6232169B2 JP 12250079 A JP12250079 A JP 12250079A JP 12250079 A JP12250079 A JP 12250079A JP S6232169 B2 JPS6232169 B2 JP S6232169B2
- Authority
- JP
- Japan
- Prior art keywords
- phenylalanine
- present
- inflammatory agent
- inflammatory
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 21
- 229930182832 D-phenylalanine Natural products 0.000 claims description 21
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 15
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 15
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229940113118 carrageenan Drugs 0.000 description 7
- 235000010418 carrageenan Nutrition 0.000 description 7
- 229920001525 carrageenan Polymers 0.000 description 7
- 239000000679 carrageenan Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000008961 swelling Effects 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229960002044 tolmetin sodium Drugs 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940090008 naprosyn Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12250079A JPS56113711A (en) | 1979-09-22 | 1979-09-22 | Antiinflammatory |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP12250079A JPS56113711A (en) | 1979-09-22 | 1979-09-22 | Antiinflammatory |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56113711A JPS56113711A (en) | 1981-09-07 |
| JPS6232169B2 true JPS6232169B2 (enExample) | 1987-07-13 |
Family
ID=14837375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP12250079A Granted JPS56113711A (en) | 1979-09-22 | 1979-09-22 | Antiinflammatory |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS56113711A (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2006070873A1 (ja) * | 2004-12-28 | 2008-06-12 | 味の素株式会社 | アディポネクチン誘導剤又は分泌促進剤 |
-
1979
- 1979-09-22 JP JP12250079A patent/JPS56113711A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56113711A (en) | 1981-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW570794B (en) | Pharmaceutical composition for preventing and treating gastrointestinal damage and disorders, ethanol withdrawal syndrome, or pain | |
| JP3305315B2 (ja) | 動物及び人間の疼痛及び／又は炎症の抑制時における薬剤ならびにその製造及びその使用 | |
| US7723389B2 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity | |
| WO2002060430A1 (en) | Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors | |
| KR20050089857A (ko) | 간암 발생 및 진행 억제제 | |
| CA2767833A1 (en) | N-acetyl cysteine compositions and methods to improve the therapeutic efficacy of acetaminophen | |
| KR930009605A (ko) | 소염 또는 진통제 | |
| JPH06501000A (ja) | グルタミンを用いるグルタチオンレベルの増大法 | |
| US6281222B1 (en) | Compositions and method for treatment of acetaminophen intoxication | |
| RU2574009C2 (ru) | Лекарственное средство для предотвращения и/или лечения гепатоклеточной карциномы | |
| JPS61129129A (ja) | 抗腫瘍剤 | |
| JP2006298929A (ja) | 炎症性疾患の処置用医薬の製造におけるガバ類縁体、たとえばガバペンチンの使用 | |
| JP5161472B2 (ja) | 鎮痛用組成物 | |
| Yeong et al. | The effects of comfrey derived pyrrolidine alkaloids on rat liver | |
| US3591686A (en) | Anti-inflammatory compositions and methods utilizing n-acylcysteines and the beta-alkyl and carboxyl derivatives thereof | |
| JPS6232169B2 (enExample) | ||
| JPH0314812B2 (enExample) | ||
| Donaubauer et al. | Acute, subchronic and chronic toxicity of the new angiotensin converting enzyme inhibitor ramipril | |
| JPS648602B2 (enExample) | ||
| DK166343B (da) | Forbedret piroxicamholdigt laegemiddel | |
| JP2001500525A (ja) | ２−メチル−チアゾリジン−２，４−ジカルボン酸及びパラセタモールからなる化合物調製物 | |
| KR20120125993A (ko) | Ｃ형 간염 바이러스 양성 사람 간경변 환자용 간암 발생·진전 억제제 | |
| EP0059031B1 (en) | Analgesic and anti-inflammatory composition | |
| US4613588A (en) | Benzaldehyde and 4,6-O-benzylidene-D-glucose for alleviating pain | |
| EP0004040B1 (en) | Pharmaceutical compositions having analgesic properties comprising a compound selected from d- and dl-phenylalanine, d- and dl-leucine and hydrocinnamic acid in the unit dose of at least 200mg |